Evaluation of tumoral enhancement by superparamagnetic iron oxide particles: comparative studies with ferumoxtran and anionic iron oxide nanoparticles.
This study was designed to compare tumor enhancement by superparamagnetic iron oxide particles, using anionic iron oxide nanoparticles (AP) and ferumoxtran. In vitro, relaxometry and media with increasing complexity were used to assess the changes in r2 relaxivity due to cellular internalization. In vivo, 26 mice with subcutaneously implanted tumors were imaged for 24 h after injection of particles to describe kinetics of enhancement using T1 spin echo, T2 spin echo, and T2 fast spin echo sequences. In vitro, the r2 relaxivity decreased over time (0-4 h) when AP were uptaken by cells. The loss of r2 relaxivity was less pronounced with long (Hahn Echo) than short (Carr-Purcell-Meiboom-Gill) echo time sequences. In vivo, our results with ferumoxtran showed an early T2 peak (1 h), suggesting intravascular particles and a second peak in T1 (12 h), suggesting intrainterstitial accumulation of particles. With AP, the late peak (24 h) suggested an intracellular accumulation of particles. In vitro, anionic iron oxide nanoparticles are suitable for cellular labeling due to a high cellular uptake. Conversely, in vivo, ferumoxtran is suitable for passive targeting of tumors due to a favorable biodistribution.
Brillet
P-Y
PY
Department of Radiology, Hôpital Avicenne, Bobigny, France. pierre-yves.brillet@avc.ap-hop-paris.fr
Gazeau
F
F
Luciani
A
A
Bessoud
B
B
Cuénod
C-A
CA
Siauve
N
N
Pons
J-N
JN
Poupon
J
J
Clément
O
O
D000230:Adenocarcinoma / Q000378:metabolism / Q000473:pathology*; D000818:Animals; D003287:Contrast Media / Q000493:pharmacokinetics; D003911:Dextrans; D004195:Disease Models, Animal; D004578:Electron Spin Resonance Spectroscopy; D045604:Extracellular Fluid / Q000378:metabolism; D052203:Ferrosoferric Oxide; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D007424:Intracellular Fluid / Q000378:metabolism; D007501:Iron / Q000493:pharmacokinetics; D058185:Magnetite Nanoparticles; D008297:Male; D051379:Mice; D008819:Mice, Nude; D049329:Nanostructures; D009368:Neoplasm Transplantation; D010087:Oxides / Q000493:pharmacokinetics; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology*; D012878:Skin Neoplasms / Q000378:metabolism / Q000473:pathology; D013057:Spectrum Analysis; D014018:Tissue Distribution; D014407:Tumor Cells, Cultured
D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; D010087:Oxides; C097921:ferumoxtran-10; D007501:Iron; D052203:Ferrosoferric Oxide
Eur Radiol. 1998;8(7):1198-204
9724439
J Magn Reson Imaging. 1994 May-Jun;4(3):301-7
8061425
Magn Reson Med. 1995 Feb;33(2):200-8
7707910
J Magn Reson Imaging. 1993 Jul-Aug;3(4):641-8
8347958
Biomaterials. 2003 Mar;24(6):1001-11
12504522
AJR Am J Roentgenol. 1994 Jan;162(1):201-7
8273666
Magn Reson Med. 2000 May;43(5):633-9
10800026
Magn Reson Imaging. 1994;12 (3):433-42
8007773
Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15256-61
10611372
Eur Radiol. 2001;11(11):2319-31
11702180
Eur Biophys J. 2002 May;31(2):118-25
12012115
Radiology. 2001 Feb;218(2):562-9
11161179
Radiology. 2003 Aug;228(2):480-7
12819345
J Colloid Interface Sci. 1997 Oct 15;194(2):427-33
9398425
J Magn Reson Imaging. 1999 Sep;10 (3):468-73
10508310
AJR Am J Roentgenol. 1995 May;164(5):1147-52
7717222
J Magn Reson Imaging. 1997 Nov-Dec;7(6):1140-5
9400860
Nat Biotechnol. 2000 Apr;18(4):410-4
10748521
J Magn Reson Imaging. 2000 Dec;12 (6):866-72
11105024
Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3030-5
11867752
Eur Radiol. 2004 Oct;14 (10 ):1851-8
15249981
Nat Biotechnol. 2001 Nov;19(11):1013-7
11689841
Magn Reson Med. 2003 Apr;49(4):646-54
12652535
Radiology. 2000 Feb;214(2):568-74
10671613
Biometrics. 1988 Sep;44(3):837-45
3203132
Magn Reson Med. 1989 Jun;10(3):289-301
2733587
J Magn Reson Imaging. 1997 Jan-Feb;7(1):258-63
9039625
J Control Release. 2001 Jul 6;74(1-3):7-25
11489479
Radiology. 1998 Jun;207 (3):799-808
9609907
Invest Radiol. 1992 Jun;27(6):450-5
1376725
Invest Radiol. 2004 Jan;39(1):56-63
14701989
Cancer Res. 1995 Sep 1;55(17):3752-6
7641188
Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4607-12
9539785